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Abstract
Early diagnosis is one of the most determining factors
for patient survival. The detection of telomerase activity
is a potentially promising tool in the diagnosis of
bladder and other types of cancer due to the high
expression of this enzyme in tumor cells. We carried out
a quantitative evaluation of telomerase activity in urine
samples in an attempt to determine a cut-off capable of
identifying cancer patients. Telomerase activity was
quantified by fluorescence TRAP assay in urine from 50
healthy volunteers and in urine and bioptic tumor
samples from 56 previously untreated bladder cancer
patients and expressed in arbitrary enzymatic units
(AEU). Telomerase activity in urine ranged from 0 to 106
AEU (median 0) in healthy donors and from 0 to 282 AEU
(median 87) in patients with cancer. A telomerase
expression higher than the cut off value determined by
receiver operating characteristic (ROC) analysis was
observed in 78% of cases, regardless of tumor grade
and in 71% (15/21) of cases of nonassessable or
negative cytology. The quantitative analysis of telomer-
ase activity in urine enabled us to define cut-off values
characterized by different sensitivity and specificity.
Cytologic and telomerase determination, used sequen-
tially, enabled us to detect about 90% of tumors.
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Introduction
Early diagnosis of bladder cancer is one of the most
determining factors for patient survival; the frequency of
recurrence and tumor progression depends to a great
extent on tumor grade and stage at time of diagnosis
[1,2 ].
Cystoscopy is the standard procedure routinely used for
the detection of bladder cancer. However, it represents an
invasive, uncomfortable, and expensive procedure and
cannot be used for screening programs.
Cytology is a cheaper, noninvasive procedure routinely
used for diagnosis, but it has only a 50% sensitivity and many
tumors, mainly of low grade, may be missed [3].
Therefore, noninvasive methods for bladder cancer
diagnosis are warranted.
Immunohistochemical evaluation of anti -Lewis X antigen
has revealed a good overall sensitivity and specificity,
especially when combined with cytology, but it has yet to
receive widespread acceptance [4]. Alternative markers,
such as Bard bladder tumor antigen (BTA), have not shown
satisfactory sensitivity and specificity [5,6].
In recent years, a great deal of information has been
accumulated on the molecular alterations that take place
during the development of bladder tumors, such as gene
mutations or genomic rearrangements. Pilot studies on p53
and ras gene mutations or CD44 variant have highlighted the
possibility to detect tumor alterations in exfoliated urine cells
[7–9]. Moreover, Mao et al. [10], Linn et al. [11], and Steiner
et al. [12] have detected microsatellite alterations in urine
samples, and new methodological approaches have recently
been developed [13].
However, individual tumors harbor specific mutations and
the overall analysis of more than one gene mutation or
microsatellite loci is needed to reach a high sensitivity.
A potentially promising tool for the diagnosis of bladder
cancer is the detection of telomerase activity. The telomerase
enzyme is a ribonucleoprotein reverse transcriptase that
synthesizes the telomeric repeats located at the ends of
chromosomes [14,15]. The majority of somatic cells do not
have telomerase activity, and thus these repetitive sequen-
ces decrease with subsequent cell divisions due to the
incomplete replication of linear DNA molecules. The pro-
gressive shortening of telomeres finally reaches a critical
stage, probably correlated with cell senescence and death.
The enzyme activity is assumed to favor telomere length
maintenance and, as a consequence, to play an important
part in cell immortalization and also tumor progression
[16,17]. Telomerase reactivation has, in fact, been observed
in immortalized cell lines and in many tumor histotypes [18].
The widespread association of telomerase activity with
tumor cells has induced researchers to investigate and define
the role of the enzymatic activity present in tumor tissue or
biologic fluids as a diagnostic or prognostic marker [19,20].
In patients with bladder cancer, telomerase activity has
been determined in bladder washings and urine [21–33].
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In the present study we determined telomerase activity in
urine from patients with cancer and healthy donors by using
a quantitative evaluation.
Materials and Methods
Biologic Material
Exfoliated cell pellets from the urine of 56 patients were
collected by centrifugation, washed once in 1 ml of PBS, and
pelleted at 10,000g for 5 minutes. A fraction of urine
samples was sent to the pathologist for cytologic diagnosis
and a fraction to the laboratory for the determination of
telomerase activity. In parallel, exfoliated cell pellets from the
urine of 50 healthy volunteers were collected and processed
in the same way. All samples were stored at 708C for a
maximum of 2 months.
Bioptic tumor samples were taken from all the patients at
the time of surgery. Diagnosis of tumor was histologically
confirmed (WHO score). Three were grade I, 24 grade II,
and 29 grade III.
Cell Extract Preparation
Tissue samples were suspended in 200 l of ice-cold
TRAP lysis buffer (Tris–HCl pH 7.5 10 mM, MgCl2 1
mM, EGTA 1 mM, phenyl methylsulfonyl fluoride 0.1 mM,
 -mercaptoethanol 5 mM, 3- [ (3-cholamidopropyl ) dime-
thylamino] -1-propanesulfonate (CHAPS) 0.5% and glyc-
erol 10%), homogenized and incubated on ice for 1 hour.
The lysate was centrifuged for 20 minutes at 10,000g
at 48C. The supernatant was removed, snap frozen, and
stored at 708C [34]. Urine samples were washed with
ice-cold wash buffer (Hepes KOH pH 7.5 10 mM, MgCl2
1.5 mM, KCl 10 mM, and dithiothreitol 1 mM) and
resuspended in ice-cold TRAP lysis buffer. The suspen-
sion was incubated on ice for 1 hour and centrifuged for
20 minutes at 10,000g at 48C. The supernatant was
collected and stored as above.
The human bladder cancer cell line, MCR, established in
our laboratory and expressing high telomerase activity, was
used as positive control. Cells were isolated and washed with
PBS and wash buffer. The cells (106) were lysed in 200 l of
ice-cold TRAP lysis buffer and collected and stored as
above.
Protein concentrations of each lysate were measured with
Bio-Rad protein assay (Bio-Rad, Hercules, CA).
Fluorescence TRAP Assay
Detection of telomerase activity was performed as
described previously [34,35]. A quantity of 0.1 g of each
protein extract was assayed in 45 l of mix containing 200
M dNTPs, 10 mM Tris–HCl (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 0.004% Tween 20, 0.004 Nonidet P-40, 0.4%
glycerol, 0.1 g TS primer end- labeled with HEX (Applied
Biosystems, Foster City, CA), 0.5 g of T4 gene 32 protein
(Roche Molecular Biochemicals, Mannheim, Germany).
After incubation in a thermal cycler for 30 minutes at 238C
and an inactivation of 2 minutes at 908C, 5 l of mix
containing 2 U of ExTaq (Takara Shuzo, Kyoto, Japan), 0.1
g of CX primer, and 25 ag of an internal telomerase assay
standard of 150 bp ( ITAS) [35] were added.
An amplification was immediately run in a thermal cycler
using 32 cycles at 948C for 30 seconds, 508C for 30 seconds,
and 728C for 30 seconds.
Four microliters of PCR product with 3 l loading buffer
(blue dextran in deionized formamide and EDTA 10 mM)
were loaded onto a 5% w/v denaturing polyacrylamide gel
(acrylamide:bisaclylamide, 19:1, 7 M urea, 1TBE). Electro-
phoresis was carried out on an Applied Biosystems 373A
DNA Sequencer equipped with GeneScan 672 Collection
and Analysis software.
Telomerase products were evaluated on fluorescence
electropherograms and the area underlying the different
peaks was calculated.
Serial dilutions of protein extract of MCR cell line
corresponding to 10, 30, 100, 300, 1000, and 3000 cells were
analyzed in each assay and telomerase activity in MCR cells
was relatively expressed to activity of 100 cell equivalents and
normalized to peak of ITAS (Figure 1A and B ).
To obtain quantitative evaluations, the areas of each
sample were also normalized to the ITAS signal. The
relative telomerase activity was correlated to corresponding
mcr cell number and expressed in arbitrary enzymatic units
(AEU).
Figure 1. Representative electropherograms of serial dilution of MCR bladder cancer cell line and quantitation of telomerase ladder. (A ) Peaks corresponding to
telomeric repeats synthesized by telomerase in a serial dilution of cell extracts ( 10, 30, 100, 300, 1000, and 3000 cell equivalents ). Cell extract dilutions were
assayed in the presence of the internal standard ( ITAS ). (B ) All telomeric peak areas corresponding to a dilution were summed. This data was normalized to area of
ITAS and expressed as relative to the signal of normalized 100 cell dilution.
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All experiments were performed in duplicate and only
variations of less than 15% for individual samples were
accepted.
Statistical Analysis
Telomerase activity was considered as a continuous
variable.
The relationship between tissue telomerase level and
histologic grade was analyzed using a nonparametric
ranking statistic.
Spearman’s correlation coefficient was used to inves-
tigate the relationship between telomerase activity in urine
and tumor tissue.
The most accurate cut -off value to discriminate between
healthy donors and tumor patients was calculated using the
receiver operating characteristic (ROC) curve. In the ROC
curve the true positive rates (sensitivity ) were plotted against
the false positive rates (1-specificity ) for all classification
points.
Results
Telomerase activity determined in cell pellets from voided
urine and tumor tissue of 56 patients as well as in urine
samples from 50 healthy donors was visualized as electro-
pherograms (Figure 2 ).
Only two urine samples and two tumor samples from
56 patients contained telomerase inhibitors and were thus
classified as unassessable. Conversely, telomerase activ-
ity was evaluable in urine samples from all 50 healthy
controls.
Telomerase levels ranged from 0 to 282 AEU (median 87)
in voided urine and from 0 to 421 AEU (median 105) in tumor
tissue. Lower levels of telomerase activity from 0 to 106 AEU
(median 0) were detected in urine samples from healthy
donors. Furthermore, value distributions of telomerase
activity showed that urine levels below 40 AEU belonged to
healthy donors in 85% of cases and to patients with cancer in
only 15% of cases. However, values above 120 AEU were
detected only in patients with cancer. An overlapping in
controls and patients with cancer was observed for values
from 41 to 120 AEU, albeit with a progressive decrease in
high values in the former subset (Figure 3 ).
The ROC curve was traced to define the sensitivity and
specificity of different enzymatic levels (Figure 4 ). The
relative sensitivity and specificity of the most relevant cut -off
values are listed in Table 1.
In 9 of the 56 cancer patients, cytologic examination was
not performed because of a lack of exfoliated cells. Of the
remaining 47 patients, malignant cells were detected in 34.
Telomerase activity assay performed in urine from 21 of the
22 patients with nonassessable or negative cytology
confirmed the good specificity and a slightly lower but
nonetheless high sensitivity observed for the TRAP assay on
the overall series (Table 1).
Side analyses were performed to investigate the relation
between telomerase activity in urine and in tumors or as a
function of tumor grade. Matched values in urine and tumors
from individual patients showed no correlation ( r s=0.34). In
our case series 24 and 27 (94%) tumors showed grade 2
and grade 3 scores, respectively, and grade 1 was observed
in only three cases. The median values of telomerase activity
Figure 2. TRAP assay of urine samples. Lanes 1, 2, and 3 show a
representative electropherogram of positive urine cell extracts. Lane 4 shows
the result of negative control, only one peak corresponding to ITAS is
observed.
Figure 3. Distribution of telomerase activity values in urine from healthy
donors and tumor patients.
Figure 4. ROC curve of telomerase activity in urine.
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in urine were 80, 83.5, and 92 for patients with grades 1, 2,
and 3 tumors, respectively, that is, AEU values showed only
a trend but did not diminish with increasing tumor differ-
entiation. It is worthy of note that the three patients with
grade 1 tumors showed very high telomerase levels (77, 80,
141 AEU; mean 99.33 AEU and standard deviation 36.11
AEU) in urine.
Discussion
The simplest and most widely used approach for the
detection of bladder cancer is the cytomorphologic exami-
nation of cells in urine. However, this method shows a low
sensitivity for low-grade tumors and a variability in sensitivity
and specificity, depending on the expertise of the cytopa-
thologist [36]. At present, cystoscopy is the most sensitive
and specific method but it is also invasive, extremely
uncomfortable, and is not applicable for screening or
disease-monitoring purposes.
Recently, telomerase activity has been proposed as a
marker of bladder tumor cells as it is present in a large
number of different tumor histotypes [19,20].
The study of this enzyme activity in bladder tissue has
been marked by different steps characterized by different
objectives and by an evolution of methods from qualitative to
quantitative. Initially, the studies aimed to analyze telomer-
ase activity in bladder cancer and surrounding macroscopi-
cally healthy tissue in relation to that present in washings and
urine samples [22,25,37,38]. In a second step, the main
objective was to verify whether this enzyme activity could
offer a reliable and noninvasive diagnostic tool [23,24,26–
33]. Because not only cancer cells but also some cells from
healthy tissue or benign lesions exhibit telomerase activity,
quantitative methods have been developed to define thresh-
old values. Telomerase activity in washings and urine has
also been investigated for its potential role in monitoring
postsurgical residual disease or in predicting tumor recur-
rence [27,30,39,40].
The information from the first body of studies clearly
shows that telomerase activity is virtually absent in normal
bladder tissue, rare in benign lesions when not associated
with a serious inflammatory situation, and frequent in tumors.
In particular, telomerase activity has been observed in 85%
to 100% of bladder tumors and in a variable percentage (0%
to 70%) of microscopically healthy adjacent tissue, probably
as a consequence of the extent of surgery or of multifocality
[21,22,28,31,33].
Furthermore, the results from different studies have
almost always shown that tumor telomerase activity is not
related to grade, size, or stage and that it is less frequently
present in biologic fluids. Among these, a lower frequency is
observed in urine with respect to washings [21,22,33,38].
In prospect of using telomerase activity for diagnostic
purposes, sensitive and quantitative approaches are needed
to avoid false-negative and false-positive results. In the
present study we evaluated telomerase activity in voided
urine from an adequate series of healthy volunteers and
patients with bladder cancer. The presence of telomerase
activity was also observed in the former group, but the
quantitative determination and statistical analysis we used
enabled us to identify different cut -off values characterized
by different sensitivity and specificity. Equally as important,
telomerase activity higher than the best cut -off value
determined by ROC analysis was observed in 71% of cases
of unassessable or negative cytology.
In conclusion, the method we are proposing is highly
reproducible, does not miss low-grade tumors, and, more
importantly, if performed after cytologic evaluation, succeeds
in unmasking the presence of tumors in cytologically
negative cases.
Our final goal is to improve the potential of such a
noninvasive approach by enlarging the case series to include
more grade I tumors and by investigating the alternative or
additional information that the expression of hTERT protein
can provide.
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